AbbVie Stock News

AbbVie and several other drugmakers are expected to announce on Friday agreements with the U.S. government to lower certain prescription drug prices and meet other demands made by President Donald Trump, according to sources familiar with the situation.

Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materially decreased our position as we evaluate this specific risk.

With its diverse product line, AbbVie is a terrific dividend stock with a solid underlying business. Eli Lilly is growing its top line incredibly rapidly and expanding into other therapeutic areas.

Building wealth through dividends requires more than chasing high yields. The path to “getting rich” combines meaningful current income with consistent dividend growth, backed by sustainable business fundamentals.

One of these pharmaceutical leaders overcame a major obstacle and has a strong outlook. The other is actively pushing greater innovation to get around a rapidly approaching patent cliff.

Dividend investing rewards patience. The best dividend stocks don't just pay consistently—they raise payouts year after year, compounding income for shareholders who stay the course.

The wall of worry continues to grow as investors race into 2026. Concentration risk is one that may not get talked about enough.

Bank of America's low payout ratio means this is a dividend you can count on. AbbVie's raking in money with immunology drugs Skyrizi and Rinvoq.